David Perry Appointed VP of Business Development at Aligos Therapeutics

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a biopharmaceutical company focused on developing innovative therapies for liver and viral diseases, has announced the appointment of David Perry as its new Vice President of Business Development, effective immediately.

Lesley Ann Calhoun, Executive Vice President and Chief Financial Officer of Aligos, expressed enthusiasm about Perry’s arrival, noting that his expertise in forging strategic partnerships will play a key role as the company seeks to optimize its advanced pipeline, particularly highlighting ALG-055009, which recently reported positive topline data.

Perry shared his excitement about joining Aligos at this pivotal moment in its growth, emphasizing his commitment to advancing the company’s drug candidates to improve patient outcomes.

With over 20 years of experience in the life sciences sector, Perry has a strong background in corporate strategy, business development, and investment management. He previously served as Senior Director of Business Development at Sangamo Therapeutics, where he played a key role in strategic partnerships, including a significant licensing deal with Genentech involving a blood-brain barrier AAV delivery platform. Perry also held leadership positions at Apexigen Inc., where he managed partnerships and led strategic initiatives that resulted in its acquisition by Pyxis Oncology. Earlier in his career, he worked in corporate development at Sumitomo Chemical and began his career in healthcare investment banking at Asante Partners. Perry holds a B.S. in environmental engineering from Tufts University.